OBJECTIVES: To assess to what extent QoL results obtained through a generic instrument (EQ-5D) correlate with those captured by a disease-sensitive measure (QoL-Assessment of Growth Hormone Deficiency in Adults). METHODS: Data were collected through a mailing survey to a random sample (n=2990;) of the Swedish population. The questionnaire comprised EQ-5D and QoL-AGHDA. QoL-AGHDA is a 25-item measure that elicits yes/no responses to personal statements describing problems that characterize aspects of HrQoL in growth hormone deficiency. A high QoL-AGHDA score denotes poor HrQoL. EQ-5D is a well-known and widely recognized generic instrument. (EuroQoL Group, 1990). The response rate was 65% and complete data on EQ-5D and QoL-AGHDA were obtained from 1665 (48.2% males; mean age 49.5, range 18-85 years) respondents. RESULTS: For EQ-5D dimensions: 11% respondents reported problems with mobility, 2% with self care, 9% usual activities, 46% pain/discomfort and 30% anxiety/depression. All results were weighted to represent the Swedish population profile with respect to age and gender. The mean EQ-5D VAS score was 80 (SD 17.3) and the mean QoL-AGHDA score was 3.9 (SD 4.8). There was a significant correlation between QoL-AGHDA scores and EQ-5D VAS (r=-0.56, p<0.001). CONCLUSIONS: These results show that there is strong correlation between results generated by a disease-sensitive and a generic measure, and thus suggest that using generic instruments for QoL assessments in specific conditions yield reliable results that could be employed for pharmacoeconomic evaluations.